Consultancy: Pitch Deck & Data Room

The Esco Lifesciences Group has a proven track record in fundraising, having successfully raised USD 200 million in 2021. At that time, Esco Aster was part of the Group before becoming an independent affiliate following its carve-out on 8 August 2022.

Since then, Esco Aster has worked closely with the global biotechnology ecosystem to help innovative companies secure strategic capital aligned with their development and manufacturing objectives.

Beyond fundraising support, we prepare companies for investment by developing compelling investor materials, structuring data rooms, and building robust business strategies that enable successful fundraising from Angel, Pre-Seed, Seed, Series A, and Series B investors.

Esco Aster is an integrated bio-innovation venture accelerator built around a single, linearly scalable biomanufacturing platform. By combining venture funding, cGMP manufacturing, strategic partnerships, industry networks, and growth capital within one ecosystem, we enable biotechnology companies to progress seamlessly from discovery through clinical development and commercial manufacturing without changing manufacturing platforms.

This integrated and capital-efficient model reduces technical and execution risk, shortens development timelines, and maximizes value creation for founders, investors, and public-sector partners.

Pitch Deck Development

A well-structured investment narrative is fundamental to successful fundraising. Esco Aster works with founders to develop investor-ready materials that communicate scientific innovation alongside commercial potential, regulatory strategy, manufacturing readiness, and long-term value creation.

Our consulting services typically begin with a comprehensive gap analysis of the existing pitch deck, business plan, data room, and supporting materials.

We then develop a tailored fundraising strategy aligned with the company's stage of development, target investors, and long-term exit objectives.

Our multidisciplinary team combines expertise in biotechnology, clinical development, CMC, MSAT, regulatory affairs, manufacturing, commercialization, and venture financing to ensure companies are positioned for both technical and commercial success.

We also leverage our network across Singapore's innovation ecosystem — including government grant agencies, universities, technology transfer offices, incubators, accelerators, family offices, accredited investors, and venture capital funds — to help founders access both non-dilutive and equity financing.

Depending on the fundraising stage and target audience, Esco Aster develops multiple investor presentations, including:

• Executive teaser deck / elevator pitch
• Non-confidential investor deck
• Confidential investor presentation
• Corporate presentation
• Co-Development Licensing Deck (optional)
• ESG Decks for Impact Funds/Nonprofits (optional)

Each presentation is tailored to its intended audience while maintaining a consistent investment narrative and milestone-driven fundraising strategy.

Where appropriate, Esco Aster's manufacturing and consulting services are incorporated into the company's use of proceeds, ensuring fundraising plans are directly aligned with product development and commercialization milestones, as well as a comprehensive business plan.

Business Plan Deliverables

• Fundraising strategy and investment roadmap
• Comprehensive gap assessment
• Business plan
• Revenue model
• Financial projections
• Go-to-market strategy
• Use of proceeds
• Milestone planning
• Exit strategy
• Investor Q&A preparation

Virtual Data Room Architecture Development

Beyond preparing investor presentations, Esco Aster designs and structures comprehensive virtual data rooms that support institutional due diligence and significantly improve fundraising efficiency.

Our data rooms are designed to present information logically and professionally, enabling investors to efficiently evaluate the scientific, operational, regulatory, commercial, and financial strengths of the company.

Working backwards from clearly defined value-inflection points and exit objectives, we help founders establish fundraising milestones from company formation through acquisition or IPO. Our framework and bio-innovation accelerator is designed to support ventures requiring less than USD 30 million in equity financing, excluding non-dilutive funding such as government grants, research funding, foundations, philanthropic organizations, and other innovation support programs.